Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.

By A. Mebazaa, M. Nieminen, M. Packer, A. Cohen-Solal, F. Kleber, Stuart J. Pocock, R. Thakkar, R. Padley, P. Poder, M. Kivikko. Journal of the American Medical Association (JAMA), 2007

1,017 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/d21d2fc3836166ca4884607bd0fb28ad09c5bfa1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Gheorghiade
2. G. Fonarow
3. M. Flemmer
4. P. Marik
5. T. Horwich
6. J. Januzzi
7. C. Yancy
8. M. Drazner

Citations in the corpus

• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, neutral): “Levosimendan treatment is associated with a slight increase in heart rate and a decrease in the BP, especially if a loading dose is administered.(235,237) Levosimendan may be administered as a bolus dose (3–12 mg/kg) during 10 min followed by a continuous infusion (0.”
• Narrative Review (2012, background): “b-receptor agonists (eg, dobutamine) and phosphodiesterase III isoenzyme inhibitors (eg, milrinone) are currently recommended and are widely used in the treatment of patients with ADHF.9,11 b-receptor agonists activate adenyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) wh”
• CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration (2008, neutral): “‘‘Main outcome measure: all-cause mortality at 180 days’’ [38].”
• Acute heart failure syndromes (2009, background): “In patients dmitted with very severe HF, levosimendan was not uperior to dobutamine in terms of post-discharge mortality hat was very high in both groups (72).”
• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “BNP and NT-proBNP levels improve with treatment of chronic HF (225, 272-274), with lowering of”